Ekso Bionics shares surge 40.27% premarket after securing exclusive U.S. distribution deal for MediTouch's BalanceTutor rehabilitation system.

Ekso Bionics Holdings Inc. (EKSO) surged 40.27% in premarket trading following the announcement that it secured an exclusive U.S. distribution agreement for MediTouch’s BalanceTutor rehabilitation system. The deal positions Ekso Bionics as the sole distributor of the innovative 4D perturbation treadmill, which simulates balance challenges for rehabilitation. The company emphasized the BalanceTutor’s strategic alignment with its existing exoskeleton solutions, enabling cross-selling to physical rehabilitation facilities. CEO Scott Davis highlighted the partnership’s potential to expand patient care offerings, while MediTouch’s VP of Global Business Development noted the collaboration’s significance in broadening access to its technology. The agreement, described as a major milestone, underscores Ekso Bionics’ growth strategy in the medical exoskeleton market, driving strong premarket enthusiasm.